Table 6.
Comparison of economic costs among UC patients using Kruskal-Wallis tests and Mann-Whitney
| Variables | DMC $ | DNMC $ | IC $ | Total costs $ |
|---|---|---|---|---|
| Total | Mean(95% CI) | Mean(95% CI) | Mean(95% CI) | Mean(95% CI) |
| Gender | ||||
| Women | 1084.61(924.48-1244.74) | 496.26(367.37-625.15) | 749.22(588.31-910.14) | 2330.09(2057.79-2602.39) |
| Men | 1222.57(1072.96-1372.18) | 482.91(377.63-588.20) | 598.67(466.44-730.89) | 2304.15(2059.44-2548.86) |
| Age Group | ||||
| ≤20 | 1038.39(670.33-1406.45) | 499.55(40.92-958.18) | 1438.62(474.68-3351.93)* | 2976.56(639.35-5313.77)* |
| 21 – 40 | 1215.45(1064.83-1366.07) | 474.96(383.03-566.88) | 699.42(574.79-824.05) | 2389.83(2170.45-2609.21) |
| 41 – 60 | 1100.53(942.72-1258.34) | 579.32(352.91-805.73) | 603.33(411.24-795.41) | 2283.18(1900.85-2665.50) |
| >60 | 816.61(588.72-1044.50) | 345.63(71.53-619.74) | 387.71(88.16-687.26) | 1549.96(989.82-2110.10) |
| Marital status | ||||
| Unmarried | 1051.91(941.54-1162.28) | 422.28(287.04-557.53) | 585.40(384.24-786.57) | 2059.59(1776.05-2343.13) |
| Married | 1204.43(1054.69-1354.16) | 535.05(428.89-641.21) | 704.90(579.01-830.79) | 2444.38(2210.36-2678.39) |
| Separated /widowed | 967.73(606.51-1328.94) | 149.48(22.52-276.45) | 678.92(123.53-1234.32) | 1796.13(1119.61-2472.66) |
| Occupation status | ||||
| Homemakers | 1029.77(898.29-1161.26) | 523.69(366.44-680.95) | 827.72(622.52-1032.92) | 2381.19(2050.91-2711.46) |
| Disabled | 1710.28(1106.70-2313.85) | 273.15(687.46-1233.76) | 330.29(724.67-1385.26) | 2313.72(43.16-4670.60) |
| Retired | 1096.78(710.38-1483.18) | 471.73(152.10-791.36) | 425.27(132.51-718.04) | 1993.79(1221.53-2766.05) |
| Unemployed | 1041.14(930.96-1151.31) | 470.02(286.78-653.26) | 623.36(417.26-829.46) | 2134.52(1795.90-2473.14) |
| Student | 1161.95(818.32-1505.58) | 589.14(259.80-918.48) | 767.24(103.70-1430.79) | 2518.33(1697.74-3338.92) |
| Employed | 1316.18(1050.67-1581.68) | 463.91(319.39-608.44) | 610.36(443.68-777.04) | 2390.45(2051.68-2729.23) |
| Residential area | ||||
| Village | 1204.03(987.09-1420.96) | 399.36(274.26-524.46) | 734.10(515.30-952.89) | 2337.48(1966.52-2708.44) |
| Urban | 1141.64(1015.37-1267.92) | 513.44(414.45-612.44) | 656.35(538.05-774.64) | 2311.43(2102.36-2520.50) |
| Education | ||||
| Illiterate | 1301.38(809.19-1793.58) | 430.09(29.23-830.96) | 510.91(197.38-824.44) | 2242.39(1367.52-3117.25) |
| Less than 6 years | 1438.37(979.41-1897.33) | 587.06(250.49-923.62) | 483.72(83.73-883.70) | 2509.14(1692.36-3325.92) |
| 6–12 years | 1056.01(936.97-1175.05) | 446.75(337.68-555.83) | 772.98(608.77-937.18) | 2275.74(2026.33-2525.16) |
| More than12 years | 1188.35(1007.80-1368.89) | 512.65(382.84-642.47) | 628.15(478.56-777.73) | 2329.15(2048.74-2609.55) |
| Complementary insurance | ||||
| Yes | 1193.57(968.04-1419.11) | 519.98(350.60-689.35) | 729.60(516.43-942.77) | 2443.15(2061.42-2824.88) |
| No | 1134.34(1015.70-1252.98) | 473.44(383.35-563.53) | 642.76(529.81-755.71) | 2250.54(2057.09-2443.99) |
| Disease Duration | ||||
| <=5 | 1197.32(1059.46-1335.18) | 439.21(328.86-549.57) | 761.29(564.33-958.25) | 2397.82(2096.33-2699.31) |
| 5 – 10 | 1044.24(927.62-1160.86) | 440.40(287.43-593.36) | 591.88(439.66-744.10) | 2076.52(1795.96-2357.07) |
| 11 – 15 | 1314.68(843.06-1786.30) | 574.75(344.38-805.12) | 582.92(367.98-797.86) | 2472.35(1976.91-2967.80) |
| > 15 | 1072.66(892.89-1252.42) | 609.11(351.44-866.79) | 740.83(413.05-1068.62) | 2422.60(1878.42-2966.78) |
| Use of tobacco products | ||||
| Yes | 1217.23(789.23-1645.23) | 379.69(155.68-603.70) | 341.35(241.02-441.69) | 1938.27(1488.21-2388.33) |
| No | 1144.69(1036.48-1252.90) | 507.15(418.10-596.20) | 726.02(608.36-843.68) | 2377.85(2179.95-2575.75) |
| Primary drug | ||||
| IFX | 801.07(695.21-906.93) * | 590.49(415.01-765.96) | 638.83(478.00-799.66) | 2030.39(1779.62-2281.16) * |
| ADA | 1327.17(1180.00-1474.34) | 440.23(352.05-528.42) | 689.18(555.60-822.76) | 2456.58(2217.24-2695.91) |
DMC Direct medical costs, DNMC Direct non-medical costs, IC Indirect costs, CI Confidence interval, IFX Infliximab, ADA Adalimumab, *Statisticvally significant